Skip to content

Cardiac complicAtions in Patients With SARS Corona vIrus 2 (COVID-19) regisTrY

Cardiac complicAtions in Patients With SARS Corona vIrus 2 regisTrY

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04325412
Acronym
CAPACITY-COVID
Enrollment
1000
Registered
2020-03-27
Start date
2020-03-23
Completion date
2021-06-23
Last updated
2020-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19; Cardiovascular Diseases

Brief summary

CAPACITY (www.capacity-covid.eu) is a registry of patients with COVID-19 across Europe and has been established to answer questions on the role of cardiovascular disease in this pandemic. It is an extension of the Case Record Form (CRF) that was released by the ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium) and WHO (World Health Organisation) in response to the emerging outbreak of COVID-19.

Detailed description

The aim of CAPACITY is to collect data regarding the cardiovascular history, diagnostic information and occurrence of cardiovascular complications in COVID-19 patients. By collecting this information in a standardized manner, CAPACITY can aid in providing more insight in (1) the incidence of cardiovascular complications in patients with COVID-19, and (2) the vulnerability and clinical course of COVID-19 in patients with an underlying cardiovascular disease. The CAPACITY extension to the ISARIC-WHO CRF consists of additional data collection instruments for: * cardiac history and cardiovascular risk factors * prior use of cardiac medication or NSAIDs * electrocardiography (ECG) * echocardiography * cardiac MRI * invasive cardiac procedures * cardiac complications * cardiac biomarkers * cardiac outcome during admission

Interventions

None listed

Sponsors

UMC Utrecht
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Highly suspected/confirmed infection with SARS-CoV-2

Exclusion criteria

\- Patients that opt-out

Design outcomes

Primary

MeasureTime frame
The incidence of cardiovascular complications in patients with COVID-1930 days

Countries

Netherlands

Contacts

Primary ContactFolkert W. Asselbergs, MD, PhD
f.w.asselbergs@umcutrecht.nl+31 (0) 88 755 5555

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026